40216-83-9

Basic information

• Product Name: trans-4-Hydroxy-L-proline methyl ester hydrochloride
• Synonyms: H-HYP-OME HCL;H-L-HYP-OME HCL;HYDROXYPROLINE-OME HCL;L-4-HYDROXYPROLINE METHYL ESTER HYDROCHLORIDE;L-4-HYDROXYPROLINE METHYL ESTER HYDROCHLORIDE SALT;L-4-TRANS-HYDROXYPROLINE METHYL ESTER HYDROCHLORIDE;L-4-TRANS-HYDROXYPROLINE METHYL ESTER HYDROCHLORIDE SALT;L-TRANS-4-HYDROXYPROLINE METHYL ESTER HYDROCHLORIDE SALT
• CAS NO: 40216-83-9
• Molecular Formula: C₆H₁₁NO₃*ClH
• Molecular Weight: 181.62
• EINECS: 1533716-785-6
• Product Categories: Nitrogen cyclic compounds;Amino Acid Derivatives;Amino Acids;Hydroxyproline [Hyp];Peptide Synthesis;Proline Derivatives;Unnatural Amino Acid Derivatives;Amino Acids & Derivatives;Chiral Reagents;Heterocycles
• Mol File: 40216-83-9.mol
• Article Data: 99

Chemical Properties

• Melting Point: 169 °C
• Boiling Point: 247.2ºC at 760 mmHg
• Flash Point: 103.3ºC
• Appearance: /
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly), Water (Slightly, Sonicated)
• Stability: Hygroscopic
• BRN: 4716932
• CAS DataBase Reference: trans-4-Hydroxy-L-proline methyl ester hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: trans-4-Hydroxy-L-proline methyl ester hydrochloride(40216-83-9)
• EPA Substance Registry System: trans-4-Hydroxy-L-proline methyl ester hydrochloride(40216-83-9)

Safety Data

• Hazard Codes: Xi
• Safety Statements: 24/25
• WGK Germany: 3
• Hazardous Substances Data: 40216-83-9(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

trans-4-Hydroxy-L-proline (H952376) derivative. A natural constituent of animal structural proteins such as collagen and elastin.

InChI:InChI=1/C6H11NO3.ClH/c1-10-6(9)5-2-4(8)3-7-5;/h4-5,7-8H,2-3H2,1H3;1H/t4-,5+;/m1./s1

Upstream product

• 67-56-1 methanol 
• 51-35-4 4R-4-hydroxyproline 
• 77-76-9 2,2-dimethoxy-propane 
• 75-36-5 acetyl chloride 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 
• 32968-78-8 (2S,4R)-4-hydroxy-2-pyrrolidinecarboxylic acid hydrochloride 
• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 
• 51-35-4 4-hydroxyproline 

Downstream Products

• 67943-19-5 methyl (2S,4R)-1-acetyl-4-hydroxypyrrolidine-2-carboxylate 
• 129430-93-9 methyl (2S,4R)-4-hydroxy-1-tritylpyrrolidine-2-carboxylate 
• 179990-59-1 (2S,4R)-4-hydroxy-N-(9'-phenylfluoren-9'-yl)pyrrolidine-2-carboxylic acid methyl ester 
• 31560-20-0 (2S,4R)-1-benzoyl-4-hydroxypyrrolidine-2-carboxylic acid methyl ester 
• 129430-93-9 (2S,4S)-methyl 4-hydroxy-1-tritylpyrrolidine-2-carboxylate 
• 253307-68-5 1-(N-[2-(tert-butoxycarbonylamino)ethyl])-4-(R)-hydroxy-2-(S)-proline methyl ester 
• 1032196-26-1 (2S,4R)-1-butyryl-4-hydroxy-pyrrolidine-2-carboxylic acid methyl ester 
• 64187-48-0 methyl (2S,4R)-1-benzyloxycarbonyl-4-hydroxypyrrolidine-2-carboxylate 
• 172947-80-7 (2S,4R)-1-ethyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate 
• 195453-64-6 tert-butyl (2R)-1-[(benzyloxy)carbonyl]-2-{[(2S,4R)-4-hydroxy-2-(methoxycarbonyl)pyrrolidin-1-yl]carbonyl}pyrrolidine-2-acetate 
• 195453-67-9 tert-butyl (2S)-1-[(benzyloxy)carbonyl]-2-{[(2S,4R)-4-hydroxy-2-(methoxycarbonyl)pyrrolidin-1-yl]carbonyl}pyrrolidine-2-acetate 
• 164167-01-5 N-trityl-L-pyroglutamyl-D-histidyl(N^im-trityl)-trans-4-hydroxy-L-proline methyl ester 
• 164166-93-2 N-trityl-L-pyroglutamyl-L-histidyl(N^im-trityl)-trans-4-hydroxy-L-proline methyl ester 
• 132715-17-4 (2S,4R)-methyl 1-(2-chloroacetyl)-4-hydroxypyrrolidine-2-carboxylate 

Relevant articles and documents

4'-Methyloxycarbamyl-3'-deoxy-5-methyluridine; synthesis of a novel nucleoside analogue

The preparation of 4'-methyloxycarbamyl-3'-deoxythymidine from chiral amino acid precursors is described. The route chosen employs a hitherto unreported electrochemical oxidation of a suitably protected derivative of trans-4-hydroxy-L-proline, to obtain the key intermediate compound. Conventional condensation methodology is then used to arrive at the target nucleoside.

VISUAL DETECTION OF PBD INDUCED DNA CROSSLINKS

The present invention relates to the field of oncology, laboratory tools and methods, and especially anti-tumor DNA crosslinking agents. Most patients with advanced solid tumors develop resistance to chemotherapy due to the ability of cancer cells to repair or tolerate sustained DNA damages. The inventors showed that the compounds according to the present invention allow the detection and visualization of alkylated DNA damages induced by PBDs without altering their DNA crosslinking ability. This enables the study of the effect and properties of PBDs. In particular, the present invention relates new derivates of PBD molecules and their synthesis. The present invention also relates to a method for visualizing DNA crosslinking; to a method for assessing the resistance of a tumor to a crosslinking agent and to a method for identifying a molecule or treatment for improving the efficiency of a crosslinking agent.

NOVEL CONNECTED BODY AND USE THEREOF IN SPECIFIC CONJUGATION BETWEEN BIOMOLECULE AND DRUG

PROBLEM TO BE SOLVED: To provide: a method for producing a connected body; a method for using the connected body in the production of a uniform conjugate; and a method for applying the conjugate in the treatment of cancer, infectious diseases, and autoimmune diseases. SOLUTION: A novel connected body is provided that includes a 2,3-di-substituted succinic acid group or a 2-mono-substituted or 2,3-di-substituted fumaric acid or maleic acid (trans (E)- or cis (Z)-butenedioic acid) group for conjugating 2 or more compounds/cytotoxic agents per connected body with a cell-binding molecule by specifically bridge-linking to a pair of thiol on the cell-binding molecule. The connected body is exemplified by the following general formula. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT

Quinoline-Proline, Triazole Hybrids: Design, Synthesis, Antituberculosis, Molecular Docking, and ADMET Studies

A series of novel quinoline-proline hybrids (11a-g) and quinoline-proline-1,2,3-triazole hybrids (12-14) were synthesized by click chemistry based on molecular hybridization concept and were characterized by NMR, mass spectrometry, and elemental analysis. All the titled target compounds were tested for antitubercular activity by MABA and LORA methods by in vitro. Interestingly, two compounds (2R,4S)-1-((2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl)-methyl)-4-(4-nitrobenzamido)-N-phenylpyrrolidine-2-carboxamide (11b) and (2R,4S)-1-((2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl)-methyl)-4-(4-fluorobenzamido)-N-phenylpyrrolidine-2-carboxamide (11c) exhibited significant activity against the tested Mycobacterium tuberculosis H37Rv strain. Further, the cytotoxicity (CC50) profile of the titled compounds against the Vero cell was performed and discussed. A molecular docking study of the hit compounds (11b and 11c) was also performed to find their putative binding interaction with the active site of the target proteins. Finally, in silico ADMET properties were also predicted for all the synthesized molecules to evaluate their drug-likeness behavior.